Precision medicine

The multinational pharma company will now be able to access Tempus' de-identified patient data.

Alphabet's life science arm also announces the company's founder Andy Conrad will step down as CEO. Current president Stephen Gillett will take on the role in January.

The layoffs represent 13% of the AI-backed genomic and clinical data company's workforce.

Precision medicine is entering the mainstream, from genetic insights informing a range of specialties to primary care using pharmacogenomics, according to Dr. Joel Diamond of 2bPrecise.

Also: Precision oncology platform OncoHost scores $35 million, home care startup Reverence emerges from stealth with $9.5 million and pediatric behavioral health startup Handspring Health completes a $6.2 million seed round.

Also: Imagene AI raises $21.5 million across two rounds for precision cancer care, and Capable Health scores $6 million in seed funding to help providers build healthcare apps.

Also: Rupa Health raised $20 million for its lab test platform, and CancerIQ scooped up $14 million in Series B funding.

CEO and cofounder of InsightRX Sirj Goswami shares how precise dosage, determined for each patient, can improve healthcare and avoid unwanted outcomes.

The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.

The industrial giant plans to retain a stake of almost 20% in GE Healthcare.